Randomized trial evaluates reductions of troublesome dyskinesia in advanced Parkinson’s disease, suggesting effective treatment options.
To evaluate reductions of troublesome dyskinesia (TSD) in people with advanced Parkinson’s disease (aPD) following treatment with foslevodopa/foscarbidopa (LDp/CDp) in two phase 3 clinical trials.
No takes yet. Share an insight, caveat, or question.
Hauser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: